期刊文献+

阿托伐他汀钙中间体的合成工艺研究 被引量:5

Research on the synthesis of 4-(4-Fluorophenyl)-2 (2-Methylpropanoyl)-4-Oxo-N,β-Diphenylbutanamide
在线阅读 下载PDF
导出
摘要 以异丁酰乙酸甲酯为原料经苯胺胺解得到4-甲基-3-氧-N-苯戊酰胺,然后与苯甲醛发生反应,得到4-甲基-3-氧-N-苯-2-(苯亚甲基)戊酰胺,再以溴化噻唑为催化剂,与对氟苯甲醛发生Stetter反应,得到阿托伐他汀钙的关键中间体4-(4-氟苯基)-2-(2-甲基丙酰基)-4-氧代-N,β-二苯基丁酰胺.该方法操作简便,收率较高,各主要化合物结构经核磁共振氢谱确证. 4-(4-Fluorophenyl)-2-(2-methylpropanoyl)-4-oxo-N,β-diphenylbutanamide is a key intermediate of atorvastatin.Methyl isobutyryl acetate was transformed into 4-methyl-3-oxo-N-pentanamide by reaction with aniline;the resulting product could undergo Knoevenagel condensation with benzaldehyde giving 4-mehtyl-3-oxo-N-Phenyl-2-(Phenylmethylene)Pentanamide,which could further undergo Stetter reation with p-fluorobenzaldehyde thus giving aceess to the final molecule 4-(4-Fluorophenyl)-2(2-methylpropanoyl)-4-oxo-N,β-diphenylbutanamide.The synthetic route were easily available and the yield was reasonable.The structures of the main intermediates were identified by 1H NMR.
出处 《武汉工程大学学报》 CAS 2010年第12期10-12,共3页 Journal of Wuhan Institute of Technology
关键词 药物化学 化学合成 阿托伐他汀 HMG-COA还原酶抑制剂 medicinal chemistry chemical synthesis atorvastatin HMG-COA reductase inhibitor
  • 相关文献

参考文献6

  • 1黄震华.新型降脂药物阿托伐他汀[J].中国新药与临床杂志,2000,19(1):54-56. 被引量:29
  • 2周晋武,汪钊.阿伐他汀手性中间体合成研究进展[J].化学与生物工程,2008,25(5):1-4. 被引量:4
  • 3尹大力,李春.(+)对氟-2-(2-甲基-丙酰胺)4-氧-N,3-二苯基-苯丁酰胺的新合成方法以及其中的中间体:中国,1325844A[P].2001-12-12.
  • 4Kelvin L,Baumann,Donald E,et al.The convergent synthesis of CI -981,an optically active,highly potent,tissue selective inhibitor of HMG-CoA reductase[J].Tetrahedron Letters,1992:2283-2284.
  • 5Charles JK,Weissberger A.Organic Syntheses:Coll Vol 3[M].New York:John Wiley Sons Inc,1961:108-112.
  • 6Butler D E,Deering C F,Millar A,et al.Process for trans-6-[2-(substituted-Pyorrl-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis:US,5097045[P].1992-3-17.

二级参考文献30

  • 1任吉民,张立.他汀类降脂药物市场浅析[J].上海医药,2005,26(7):313-314. 被引量:5
  • 2钟萍,孙志浩.生物催化不对称还原方法生产(S)-4-氯-3-羟基丁酸乙酯[J].过程工程学报,2005,5(6):665-669. 被引量:7
  • 3金勇,吴坚平,徐刚,杨立荣.有机相酶催化氨解反应拆分制备(R)-4-氯-3-羟基丁酸乙酯[J].有机化学,2006,26(10):1384-1388. 被引量:8
  • 4[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59.
  • 5[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13.
  • 6[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D.
  • 7[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33.
  • 8[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336.
  • 9[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42.
  • 10[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47.

共引文献31

同被引文献32

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部